Skip to content

Remodeling lipid and mitochondrial homeostasis: a novel mechanism by which polydatin attenuates renal tubular senescence in chronic kidney disease.

Aug 2026 · International Immunopharmacology · Vol 188, pp. 117311 · 0 citations · 66 references
Medicine

TL;DR

PD rewires lipid metabolism, restores mitochondrial homeostasis, and activates the SIRT3/SOD2 axis to mitigate DNA damage and suppress tubular senescence, thereby halting CKD progression and position PD as a promising therapeutic candidate for senescence-associated kidney diseases.

Abstract

Tubular cell senescence is a well-recognized key driver of chronic kidney disease (CKD) pathogenesis, which imposes a substantial global health burden. Polydatin (PD) is a natural polyphenol derived from Polygonum cuspidatum, its novel potential to modulate tubular cell senescence in CKD-specifically through remodeling lipid dysfunction and restoring mitochondrial homeostasis-remains unelucidated. Our study focused on unraveling the core molecular mechanisms underlying PD driven therapeutic effects in CKD, with SIRT3 as a key target validated by tubule-specific depletion strategies in vivo. PD treatment significantly ameliorates renal dysfunction, attenuates tubular injury, and mitigates interstitial fibrosis in CKD, with consistent renoprotective effects confirmed in vitro. Transcriptomic analyses identified lipid metabolism remodeling and mitochondrial homeostasis restoration as core pathways regulated by PD, with the SIRT3/SOD2 axis emerging as a central regulatory hub. Mechanistically, PD restores SIRT3 expression, which in turn enhances SOD2 deacetylation, boosts antioxidant capacity, reverses lipid dysfunction, and ultimately reduces mitochondrial reactive oxygen species (ROS) accumulation and mitochondrial damage. Notably, PD effectively suppresses the DNA damage response via reducing γH2AX foci formation, thereby alleviating tubular cell senescence (evidenced by decreased p21 expression and SA-β-gal activity in vivo and in vitro). Critically, tubule-specific SIRT3 knockout or siRNA-mediated knockdown abrogated protective effects modulated by PD, underscoring SIRT3 as an essential mediator of its therapeutic actions. Collectively, our study unveils that PD rewires lipid metabolism, restores mitochondrial homeostasis, and activates the SIRT3/SOD2 axis to mitigate DNA damage and suppress tubular senescence, thereby halting CKD progression. These findings position PD as a promising therapeutic candidate for senescence-associated kidney diseases.

View source

Similar papers

Review Open access Aug 2026

Redox-Mediated Mitochondrial Dysfunction as a Common Pathogenic Axis in Acute Kidney Injury and Chronic Kidney Disease

Overall, redox-mediated mitochondrial injury represents a shared pathogenic axis and a potential therapeutic target across kidney diseases, and emerging biomarkers and therapeutic strategies targeting oxidative stress and mitochondrial dysfunction are discussed.

Ewelina Młynarska, K. Bojdo, Katarzyna Hossa et al. · 0 citations
#protein folding Sep 2026

Systems-level proteomic reprogramming reveals mitochondrial restoration and inhibition of Rho GTPase-mediated cytoskeletal and inflammatory signaling in CKD

It is demonstrated that DVA exerts a dual therapeutic effect by restoring essential mitochondrial and metabolic pathways while simultaneously suppressing inflammation, oxidative stress, and cytoskeletal dysregulation in CKD.

Reshma Shettigar, Shobha Dagamajalu, Hemashree Kampa et al. · 0 citations
Review Open access Sep 2026

Oxidative Stress and Mitochondrial Dysfunction in Chronic Kidney Disease: From Molecular Mechanisms to Biomarkers and Targeted Therapies

This review emphasizes not only mechanistic advances but also conflicting findings, model limitations, and the barriers that currently separate experimental efficacy from clinically meaningful CKD outcomes.

F. De Luca, Dario Troise, Valentina Camporeale et al. · 1 citation
Aug 2026

Dapagliflozin attenuates cellular senescence and mitochondrial dysfunction in diabetic kidney disease: potential involvement of AMPK/Sirt3 signaling.

Cellular senescence contributes to the pathology of diabetic kidney disease (DKD). Besides, mitochondrial dysfunction and cellular senescence are closely associated pathological processes that may influence one another during kidney injury progression. Dapagliflozin has demonstrated its renal protective benefits indepe...

Xin Tong, Bin Wang, Fen-Fei Gao et al. · 0 citations
Sep 2026

BRD2-Mediated TGR5 Destabilization Impairs Fatty Acid Oxidation and Drives Tubular Ferroptosis in Diabetic Kidney Injury.

A BRD2-TGR5-FAO signaling axis is delineated as a central pathogenic driver of tubular lipotoxicity and ferroptosis in diabetic kidney injury, and BRD2 inhibition is position as a mechanistically grounded therapeutic strategy for diabetic kidney disease.

Hui-Mei Zang, Fu-Cheng Zang, Hai-Yan Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.